Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.

There are no licensed treatments for non alcoholic fatty liver disease (NAFLD) in adults or children. In NAFLD, several studies have shown a benefit of omega-3 fatty acid treatment on lipid profile, insulin-sensitivity and hepatic steatosis and it has also been suggested that Vitamin D treatment has...

Full description

Bibliographic Details
Main Authors: Claudia Della Corte, Guido Carpino, Rita De Vito, Cristiano De Stefanis, Anna Alisi, Stefano Cianfarani, Diletta Overi, Antonella Mosca, Laura Stronati, Salvatore Cucchiara, Massimiliano Raponi, Eugenio Gaudio, Christopher D Byrne, Valerio Nobili
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5158039?pdf=render
id doaj-756e8385780b492bb10a542c03444926
record_format Article
spelling doaj-756e8385780b492bb10a542c034449262020-11-25T02:47:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011112e016821610.1371/journal.pone.0168216Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.Claudia Della CorteGuido CarpinoRita De VitoCristiano De StefanisAnna AlisiStefano CianfaraniDiletta OveriAntonella MoscaLaura StronatiSalvatore CucchiaraMassimiliano RaponiEugenio GaudioChristopher D ByrneValerio NobiliThere are no licensed treatments for non alcoholic fatty liver disease (NAFLD) in adults or children. In NAFLD, several studies have shown a benefit of omega-3 fatty acid treatment on lipid profile, insulin-sensitivity and hepatic steatosis and it has also been suggested that Vitamin D treatment has potential antifibrotic properties in liver disease.To date, however, there are no studies that have tested the combination of Docosahexanoic acid (DHA) and vitamin D treatment which may benefit the whole spectrum of disease in NAFLD. Our aim therefore, was to test the effect of daily DHA (500 mg) plus vitamin D (800 IU) treatment, in obese children with biopsy-proven NAFLD and vitamin D deficiency, in a randomized, double-blind placebo-controlled trial.The 41/43 patients completed the study (18-treatment, 23-placebo). At 12 months: i) the main outcome was liver histology improvement, defined by NAS; ii) the secondary outcome was amelioration of metabolic parameters.DHA plus vitamin D treatment reduced the NAFLD Activity Score (NAS), in the treatment group (5.4 v1.92; p<0.001 for baseline versus end of study). There was no change in fibrosis score, but a reduction of the activation of hepatic stellate cells (HSC) and fibrillar collagen content was noted (3.51±1.66 v. 1.59±1.37; p = 0.003) in treatment group. Moreover, the triglycerides (174.5 vs. 102.15 mg/dl), ALT (40.25 vs. 24.5 UI/l) and HOMA-IR (4.59 vs. 3.42) were all decreased with treatment.DHA plus vitamin D treatment improved insulin-resistance, lipid profile, ALT and NAS. There was also decreased HSC activation and collagen content with treatment.http://europepmc.org/articles/PMC5158039?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Claudia Della Corte
Guido Carpino
Rita De Vito
Cristiano De Stefanis
Anna Alisi
Stefano Cianfarani
Diletta Overi
Antonella Mosca
Laura Stronati
Salvatore Cucchiara
Massimiliano Raponi
Eugenio Gaudio
Christopher D Byrne
Valerio Nobili
spellingShingle Claudia Della Corte
Guido Carpino
Rita De Vito
Cristiano De Stefanis
Anna Alisi
Stefano Cianfarani
Diletta Overi
Antonella Mosca
Laura Stronati
Salvatore Cucchiara
Massimiliano Raponi
Eugenio Gaudio
Christopher D Byrne
Valerio Nobili
Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
PLoS ONE
author_facet Claudia Della Corte
Guido Carpino
Rita De Vito
Cristiano De Stefanis
Anna Alisi
Stefano Cianfarani
Diletta Overi
Antonella Mosca
Laura Stronati
Salvatore Cucchiara
Massimiliano Raponi
Eugenio Gaudio
Christopher D Byrne
Valerio Nobili
author_sort Claudia Della Corte
title Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
title_short Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
title_full Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
title_fullStr Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
title_full_unstemmed Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
title_sort docosahexanoic acid plus vitamin d treatment improves features of nafld in children with serum vitamin d deficiency: results from a single centre trial.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description There are no licensed treatments for non alcoholic fatty liver disease (NAFLD) in adults or children. In NAFLD, several studies have shown a benefit of omega-3 fatty acid treatment on lipid profile, insulin-sensitivity and hepatic steatosis and it has also been suggested that Vitamin D treatment has potential antifibrotic properties in liver disease.To date, however, there are no studies that have tested the combination of Docosahexanoic acid (DHA) and vitamin D treatment which may benefit the whole spectrum of disease in NAFLD. Our aim therefore, was to test the effect of daily DHA (500 mg) plus vitamin D (800 IU) treatment, in obese children with biopsy-proven NAFLD and vitamin D deficiency, in a randomized, double-blind placebo-controlled trial.The 41/43 patients completed the study (18-treatment, 23-placebo). At 12 months: i) the main outcome was liver histology improvement, defined by NAS; ii) the secondary outcome was amelioration of metabolic parameters.DHA plus vitamin D treatment reduced the NAFLD Activity Score (NAS), in the treatment group (5.4 v1.92; p<0.001 for baseline versus end of study). There was no change in fibrosis score, but a reduction of the activation of hepatic stellate cells (HSC) and fibrillar collagen content was noted (3.51±1.66 v. 1.59±1.37; p = 0.003) in treatment group. Moreover, the triglycerides (174.5 vs. 102.15 mg/dl), ALT (40.25 vs. 24.5 UI/l) and HOMA-IR (4.59 vs. 3.42) were all decreased with treatment.DHA plus vitamin D treatment improved insulin-resistance, lipid profile, ALT and NAS. There was also decreased HSC activation and collagen content with treatment.
url http://europepmc.org/articles/PMC5158039?pdf=render
work_keys_str_mv AT claudiadellacorte docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT guidocarpino docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT ritadevito docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT cristianodestefanis docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT annaalisi docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT stefanocianfarani docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT dilettaoveri docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT antonellamosca docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT laurastronati docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT salvatorecucchiara docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT massimilianoraponi docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT eugeniogaudio docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT christopherdbyrne docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
AT valerionobili docosahexanoicacidplusvitamindtreatmentimprovesfeaturesofnafldinchildrenwithserumvitaminddeficiencyresultsfromasinglecentretrial
_version_ 1724751849848832000